Sign up to save your podcasts
Or
Share Balancing Innovation and Practicality in Immuno-Oncology Dose Selection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Balancing Innovation and Practicality in Immuno-Oncology Dose Selection
About this podcast:
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies.
For more information, go to IO360summit.com.
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies.
For more information, go to IO360summit.com.
View all episodes
By Conference ForumAbout this podcast:
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies.
For more information, go to IO360summit.com.
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies.
For more information, go to IO360summit.com.